請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53996
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 方俊民(Jim-Min Fang) | |
dc.contributor.author | Che-Hsuan Chang | en |
dc.contributor.author | 張哲瑄 | zh_TW |
dc.date.accessioned | 2021-06-16T02:35:58Z | - |
dc.date.available | 2020-09-02 | |
dc.date.copyright | 2015-09-02 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-27 | |
dc.identifier.citation | 1. Spandidos, D. A. J. BUON. 2007, 12, S9−S12. Oncogene and tumor suppressor genes as paradigms in oncogenesis. 2. Kern, S. E.; Kinzler, K. W.; Bruskin, A.; Jarosz, D.; Friedman, P.; Prives C.; Vogelstein, B. Science 1911, 252, 1708−1711. Identification of p53 as a sequence-specific DNA-binding protein. 3. Brundiers, R.; Lavie, A.; Veit, T.; Reinsteinm J.; Schlichtung, I.; Ostermann, N.; Goody, R. S.; Konrad, M. J. Biol. Chem. 1999, 274, 35289−35292. Modifying human thymidylate kinase to potentiate azidothymidine activation 4. Anderson, D. D.; Quintero, C. M.; Stover, P. J. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 1−6. Identification of a de novo thymidylate biosynthesis pathway in mammalian mitochondria. 5. Ahmad, S. I.; Kirk, S. I.; Eisenstark, A. Annu. Rev. Microbiol. 1998, 52, 591−625. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. 6. Ayusawa, D.; Shimizu, K.; Koyama, H.; Takeishi, K.; Seno, T. J. Biol. Chem. 1983, 258, 12448−12454. Accumulation of DNA strand breaks during thymineless death in thymidylate synthase-negative mutants of mouse FM3A cells. 7. Reichard, P. Ann. Rev. Biochem. 1988, 57, 349−374. Interactions between deoxyribonucleotide and DNA synthesis. 8. Yeh, M.-T. M.S. Thesis, 2011, National Taiwan University. Synthesis and identification of novel chemosensitizers against human thymidylate kinase 9. Goulian, M.; Bleile, B.; Tseng, B. -Y. J. Biol. Chem, 1980, 255, 10630−10637. The effect of methotrexate on levels of dUTP in animal cells. 10. Longley, D. B.; Harkin, D. P.; Johnston, P. G. Nat. Rev. Cancer 2003, 3, 330−338. 5-Fluorouracil - mechanisms of action and clinical strategies. 11. Wideman, B. C.; Balis, F. M.; Godwin, K. S.; McCully, C.; Adamson P.C. Cancer Chemother: Pharmacol. 1999, 44, 439−443. The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (TomudexTM) in a nonhuman primate model. 12. Zhang, N.; Yin, Y.; Xu, S.-J.; Chen, W.-S. Molecules 2008, 13, 1551−1569. 5-Fluorouracil: mechanisms of resistance and reversal strategies. 13. Hollstein, M.; Sidransky, D.; Volgelstein, B.; Harris, C. Science 1991, 253, 49−53. p53 mutations in human cancers. 14. Ostermann, N.; Lavie, A.; Padiyar, S.; Brundiers, R.; Veit, T.; Reistein, J.; Goody, R. S.; Konrad, M.; Schlichting, I. J. Mol. Biol. 2000, 304, 43−53. Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants’ improved kinetics with the HIV prodrug metabolite AZTMP. 15. Kumar, M.; Sharma, S.; Srinivasan, A.; Singh, T. P.; Kaur, P. J. Mol. Model. 2011, 17, 1173−1182. Structure-based in-silico rational design of a selective peptide inhibitor for thymidine monophosphate kinase of mycobacterium tuberculosis. 16. Liu, Y.; Marks, K.; Cowley, G.S.; Carretero, J.; Liu, Q.; Nieland, T. J.; Xu, C.; Cohoon, T. -J.; Gao, P.; Zhang, Y.; Chen, Z.; Altabef, A. B.; Tchaicha, J. H.; Wang, X.; Choe, S.; Driggers, E. M.; Zhang, J.; Bailey, S. T.; Sharpless, N. E,; Hayes, D .N.; Patel, N. M.; Janne, P. A.; Bardeesy, N.; Engelman, J. A.; Manning B. D.; Shaw, R. -J.; Asara, J. M.; Scully, R.; Kimmelman, A.; Byers, L. A.; Gibbons, D. L.; Wistuba, II.; Heymach, J.V.; Kwiatkowski, D. J.; Kim, W. –Y.; Kung, A. L.; Gray, N. S.; Root, D. E.; Cantley, L. C.; Wong, K. -K. Cancer Discov. 2013, 8, 870−879. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. 17. Ostermann, N.; Segura-Peña, D.; Meier, C.; Veit, T.; Monnerjahn, C.; Konrad, M.; Lavie, A. Biochemistry 2003, 42, 2568−2577. Structures of human thymidylate kinase in complex with prodrugs - implications for the structure-based design of novel compounds. 18. Lavie, A.; Vetter, I. R.; Konrad, M.; Goody, R. S.; Reinstein, J.; Schlichting, I. Nat. Struct. Biol. 1997, 4, 601−604. Structure of thymidylate kinase reveals the cause behind the limiting step in AZP activation. 19. Lavie, A.; Ostermann, N.; Brundiers, R.; Goody, R. S.; Reinstein, J.; Konrad, M.; Schlichtung, I. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 14045−14050. Structural basis for efficient phosphorylation of 3’-azidothymidine monophosphate by Escherichia coli thymidylate kinase. 20. Brundiers, R.; Lavie, A.; Veit, T.; Reinstein, J.; Schlichting, I.; Ostermann, N.; Goody, R. S.; Konrad, M. J. Biol. Chem. 1999, 274, 35289−35292. Modifying human thymidylate kinase to potentiate azidothymidine activation. 21. Ostermann, N.; Schilichting, L.; Brundiers, F.; Konrad, M.; Reinstein, J.; Veit, T.; Goody, R. S.; Lavie, A. Structure 2000, 8, 629−642. Insights into the phosphoryl transfer mechanism of human thymidylate kinase gained from crystal structures of enzyme complexes along the reaction coordinate. 22. Champoux, J. J. Annu. Rev. Biochem. 2001, 70, 369−413. DNA topoisomerases - structure, function, and mechanism. 23. Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. Chem. Biol. 2010, 17, 421−433. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. 24. Nitiss, J. L. Nat. Rev. Cancer 2009, 9, 338−350. Targeting DNA topoisomerase II in cancer chemotherapy. 25. Singal, P. K.; Iliskovic, N. N. Engl. J. Med. 1998, 339, 900−905. Doxorubicin induced cardiomyopathy. 26. Engstrom, Y.; Eriksson, S.; Jildevik, I.; Skog, S.; Thelander, L.; Tribukai, B. J. Biol. Chem. 1985, 260, 9114−9116. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. 27. Fan, H.-Z.; Villegas, C.; Huang, A.-P. Cancer Res. 1998, 58, 1650−1653. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. 28. Zhang, K.-Q.; Hu, S.-Y.; Wu, J.; Chen, L.-L.; Lu, J.-M.; Wang, X.-C.; Liu, X.-Y.; Zhou, B.-S.; Yen, Y. Mol. Cancer 2009, 8, 11. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo- implication of RRM2 in angiogenesis. 29. Hartlerode, A. J.; Scully, R. Biochem. J. 2010, 423, 157−168. Mechanisms of double-strand break repair in somatic mammalian cells. 30. Filippo, J. S.; Sung, P.; Klein, H. Ann. Rev. Biochem. 2008, 77, 229−257. Mechanism of eukaryotic homologous recombination. 31. Robert, T.; Vanoli, F.; Chiolo, I.; Shubassi, G.; Bernstein, K. A.; Rothstein, R.; Botrugno, O. A.; Parazzoli, D.; Oldani, A.; Minucci, S.; Foiani, M. Nature 2011, 471, 74−79. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. 32. Hu, C.-M.; Chang, Z.-F.; Cancer Res. 2008, 68, 2831−2840. Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status. 33. Hu, C.-M.; Yeh, M.-T.; Tsao, N.; Chen, C.-W.; Gao, Q.-Z.; Chang, C.-Y.; Lee, M.-H.; Fang, J.-M.; Sheu, S.-Y.; Lin, C.-J.; Tseng, M.-C.; Chen, Y.-J.; Chang, Z.-F. Cancer Cell 2012, 22, 36−50. Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. 34. Hu, C.-M.; Chang, Z.-F. Anal. Biochem. 2010, 398, 269−271. A bioluminescent method for measuring thymidylate kinase activity suitable for high-throughput screening of inhibitors. 35. Liang, P.; Averboukh, L.; Zhu, W.; Haley, T.; Pardee, A. B. Cell Growth Differ. 1995, 6, 1333−1338. Molecular characterization of the murine thymidylate kinase gene. 36. Martineza, A.; Fernandeza, E.; Castroa, A.; Condea, S.; Rodriguez-Francoa, I.; Bañosb, J.-E.; Badia, A. Eur. J. Med. Chem. 2000, 35, 913–922. N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. 37. Martinez, A.; Alonso, M.; Castro, A.; Pe´rez, C.; Moreno, F. J. J. Med. Chem. 2002, 45, 1292–1299. First Non-ATP competitive glycogen synthase kinase 3β(GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease. 38. Guzman, M. L.; Li, X.; Corbett, C. A.; Rossi, R. M.; Bushnell, T.; Liesveld, J. L.; Hébert, J.; Young, F.; Jordan, C. J. Blood 2007, 110, 4436–4444. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 dione (TDZD-8) 39. Slomczyńska, U.; Barany, G. J. Heterocyclic Chem. 1984, 21, 241–246. Efficient synthesis of 1,2,4-dithiazolidine-3,5-diones (dithiasuccinoyl-amines) and observations on formation of 1,2,4-thiadiazolidine-3,5-diones by related chemistry. 40. Turner, E. M.; Blazer, L. L.; Neubig, R. R.; Husbands, S. M. ACS Med. Chem. Lett. 2012, 3, 146–150. Small molecule inhibitors of regulators of G protein signaling (RGS) proteins. 41. Nasim, S.; Crooks, P. A. Tetrahedron Lett. 2009, 50, 257–259. N-Chlorosuccinimide is a convenient oxidant for the synthesis of 2,4-disubstituted 1,2,4-thiadiazolidine-3,5-diones. 42. Veguillas, M.; Ribagorda, M.; Carreño, M. C. Org. Lett. 2011, 13, 656–659. Regioselective alkylation of heteroaromatic compounds with 3-methyl-2-quinonyl boronic acids. 43. Flores, M.; Bartsch, M.; Butz, T.; Siegel, W. DE 10305225 A1, 19 Aug 2004. Catalytic oxidative coupling process for the production of 2,2'-dihydroxybiphenyls from phenols with a hydrogen in the ortho position. 44. Nógrádi, K.; Wágner, G.; Domány, G.; Bobok, A.; Magdó, I.; Kiss, B.; Kolok, S.; Fónagy, K.; Gyertyán, I.; Háda, V.; Kóti, J.; Gál, K.; Farkas, S.; Keserű, G. M.; Greiner, I.; Szombathelyi, Z. Bioorg. Med. Chem. Lett. 2014, 24, 3845–3849. Thieno[2,3-b]pyridines as negative allosteric modulators of metabotropic GluR5 receptors: Hit-to-lead optimization. 45. Furdas, S. D.; Shekfeh, S.; Bissinger, E. M.; Wagner, J. M.; Schlimme, S.; Valkov, V.; Hendzel, M.; Jung, M.; Sippl, W. Bioorg Med Chem. 2011, 19, 3678–3689. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. 46. Silvi, M.; Renzi, P.; Rosato, D.; Margarita, C.; Vecchioni, A.; Bordacchini, I.; Morra, D.; Nicolosi, A.; Cari, R.; Sciubba, F.; Scarpino, S. D. M.; Bella, M. Chem. Eur. J. 2013, 19, 9973–9978. Enantioselective aza-Michael addition of imides by using an integrated strategy involving the synthesis of a family of multifunctional catalysts, usage of multiple catalysis, and rational design of experiment. 47. Chu, G. H.; Gu, M.; Cassel, J. A.; Belanger, S.; Graczyk, T. M.; DeHaven, R. N.; Conway-James, N.; Koblish, M.; Little, P. J.; DeHaven-Hudkins, D. L.; Dolle, R. E. Bioorg. Med. Chem. Lett. 2007, 17, 1951–1955. Novel malonamide derivatives as potent κ opioid receptor agonists. 48. Atanassova, I. A.; Petrov, J. S.; Balabanova, A. N.; Mollov, N. M. Synth.Commun. 1989, 19, 2947–2954. Synthesis of ureidocarboxylic acids and hydantoins by reaction of aminocarboxylic acids or their esters with trichloroacetamides. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53996 | - |
dc.description.abstract | 胸苷三磷酸(dTTP)的生成與供給在人體中是獨特且重要的。胸苷三磷酸(dTTP)的合成必須從胸苷酸(dTMP)經由胸苷酸激酶(thymidylate kinase, TMPK)進行磷酸化形成胸苷二磷酸(dTDP),接著透過核苷酸激酶催化形成胸苷三磷酸(dTTP)。然而,其他的去氧核苷三磷酸(dNTP)是藉由核糖核苷酸還原酶(ribonucleotide reductase, RNR)將核苷三磷酸(NTP)還原而得到。因此在細胞進行DNA修復及合成時,需要胸苷酸激酶及核糖核苷酸還原酶共同作用來提供足夠的去氧核苷三磷酸(dNTPs)。在以往的研究發現,抑制胸苷酸激酶的表現,可有效降低胸苷三磷酸(dTTP)的含量並伴隨尿苷三磷酸(dUTP)大量生成到DNA,使得鹼基對不平衡,進而造成細胞凋亡。小分子化合物YMU1可以有效的抑制人類胸苷酸激酶(thymidylate kinase, TMPK),並增加低劑量癌症藥物小紅莓素(doxorubicin)所誘導的細胞凋亡。 為了尋找更好的抑制劑,我根據中研院高通量藥物篩選的結果中挑選出化合物1及TDZD-8作為合成的目標。我們設計的新分子同時包含TDZD-8的五元環及YMU1的主結構,從電腦模擬來看,發現此共軛分子可分別和胸苷酸激酶的兩個位置有作用,因此我們認為它對於胸苷酸激酶的抑制活性會較YMU1來的好。本篇論文便是設計並嘗試合成此共軛分子及其衍生物,希望能找到更好的胸苷酸激酶抑制劑。 在此論文中,我首先利用自由基耦合反應建構雙苯環系統,再藉由兩步轉化得到化合物1。然而,雙苯環分子化合物1對於人類胸苷酸激酶並無任何抑制活性。接著我將重點放在YMU1–TDZD共軛化合物的合成。在成功建構TDZD衍生物後,發現它們對於人類胸苷酸激酶皆有很好的抑制效果。然而,當嘗試將TDZD衍生物接上YMU1衍生物時,發現在鹼性情況下TDZD五環會裂解成尿素衍生物。為了避免此情形,試著先將甘胺酸接上YMU1衍生物,最後一步再進行TDZD的合環反應。但利用硫醯氯在建構五環時,發現它會影響原本的YMU1主架構。儘管兩種合成途徑皆無法得到YMU1–TDZD共軛化合物,將YMU1–尿素共軛化合物進行生物活性的測試,發現它對於人類胸苷酸激酶皆有很好的抑制效果。因此再合成了四個YMU1–尿素共軛化合物,並發現它們對於人類胸苷酸激酶也都有不錯的抑制效果。 | zh_TW |
dc.description.abstract | The biosynthesis of dTDP is unique in conversion of dTMP by thymidylate kinase (TMPK), though other dNDPs are directly produced from their corresponding NDPs by ribonucleotide reductase (RNR). DNA repair requires the coordination between RNR and TMPK to supply dNTPs. Blocking the function of TMPK would cause incorporation of dUTP during DNA repair in tumor cell. Furthermore, inhibition of TMPK is found to enhance tumor lethality on treatment with anticancer drugs. The combination treatment with YMU1 and doxorubicin is effective in chemotherapy against tumor cells. In addition to YMU1, the high-throughput screening in the Genomics Research Center, Academic Sinica revealed several small molecules with high human TMPK inhibition, including TDZD-8. By computer modeling, the designed conjugated molecule containing the moieties of YMU1 and TDZD-8 shows that these two heterocyclic cores can bind to TMPK and ATP active sites, respectively. We thus proceeded with the synthesis and bioassay of the YMU1―TDZD conjugated compound for bioactivity evaluation. First, I synthesized TDZD derivatives from condensation of isocyanate and isothiocyanate and found that they all showed good hTMPK inhibition. However, attempted amide bond coupling of TDZD derivatives and YMU1 derivatives failed because the TDZD ring will decompose to urea under basic conditions. Therefore, another synthetic strategy was designed to construct amide bond first, followed by the formation of TDZD ring to prevent TDZD ring from decomposition into urea. Nevertheless, formation of TDZD ring in the presence of sulfuryl chloride also affected the YMU1 moiety. Even though YMU1–TDZD conjugated compound cannot be synthesized by these two pathways, YMU1–urea conjugated derivatives did show higher inhibition than YMU1. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:35:58Z (GMT). No. of bitstreams: 1 ntu-104-R02223110-1.pdf: 65734246 bytes, checksum: a750abe7c4543b71b62938ef2b1e3632 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Abstract in Chinese I Abstract in English III Table of contents V Index of Schemes VIII Index of Figures IX Index of Tables XIII Abbreviations XIV Chapter 1. Introduction 1 1.1 Introduction of cancer 1 1.2 Importance of dTTP in cell 2 1.3 Biosynthetic pathway of dTTP in human cell 3 1.4 Cancer treatments by blocking the supply of dTTP 4 1.5 Thymidylate kinase (TMPK) 8 1.6 Inhibition of Topoisomerases 12 1.7 Mechanism of DNA repair 16 1.8 Effect of TMPK silence 18 1.9 The role of hTMPK during DNA repair 24 1.10 High-throughput screening for hTMPK inhibitors 29 1.11 Introduction of thiadiazolidinone (TDZD) ring 33 1.12 Previous work on developing hTMPK inhibitors in our lab 36 1.12.1 Synthesis of YMU1 derivatives 36 1.12.2 Previous studies of YMU1 derivatives 38 1.12.3 Luciferase-coupled TMPK assay 40 Chapter 2. Results and Discussion 42 2.1 High-throughput screening results 42 2.2 Specific aim in this study 44 2.3 Synthesis of biphenyl compounds 45 2.4 Synthesis of YMU1−TDZD derivatives 50 2.4.1 Retrosynthesis of YMU1−TDZD conjugated compound 50 2.4.2 General synthesis of YMU1 derivatives 51 2.4.3 Synthesis of piperazine linkers 52 2.4.4 Synthesis of heterocyclic cores 52 2.4.5 Synthesis of YMU1 derivatives 54 2.4.6 Synthesis of TDZD derivatives 54 2.4.7 Decomposition of TDZD derivatives under basic conditions 59 2.4.8 Synthesis of urea-like compounds 64 2.4.9 Alternative synthetic approach to YMU1−TDZD conjugate 69 2.5 Conclusion 75 Chapter 3. Experimental Section 78 3.1 General part 78 3.2 Determination of the purity of compounds 79 3.3 Expression and purification of enzymes 79 3.4 Luciferase-coupled TMPK assay 80 3.5 Molecular Modeling 81 3.6 Synthetic procedures and characterization of compounds 81 References 121 Appendix 131 | |
dc.language.iso | en | |
dc.title | 合成人類胸苷酸激酶之抑制劑 | zh_TW |
dc.title | Synthesis of Human TMPK Inhibitors | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳平(Richard Ping Cheng),戴桓青(Hwan-Ching Tai),張智芬(Zee-Fen Chang) | |
dc.subject.keyword | 人類胸?酸激?,抑制劑, | zh_TW |
dc.subject.keyword | hTMPK,thymidylate kinase,inhibitors,TDZD, | en |
dc.relation.page | 176 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-07-27 | |
dc.contributor.author-college | 理學院 | zh_TW |
dc.contributor.author-dept | 化學研究所 | zh_TW |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 64.19 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。